论文部分内容阅读
Objective:Cervical cancer has become a major public health problem.The development of effective,systemic therapies for cervical cancer is highly desired.We show here that hypoxia inducible factor-1α(HIF-1α) was indicated as an attractive therapeutic molecular target for cervical cancer.Methods:Firstly,we observed the expressional level of HIF-1α in cervical cancer and Hela and Siha cell lines.Secondly,by constructuring HIF-1α shRNA targeting human HIF-1α mRNA common sequence and transfecting it with plasmid to cervical cell,we detected the changes of HIF-1α and its downstream genes levels VEGF.Then we injected selected stably transfected cell line into athymic nude mice to estimate its’ antitumor effects.Results:We observed that HIF-1α inhibition was related to down-regulated VEGF resulting in prevention of angiogenesis,then leading to slower-growing tumors.Conclusion:The underlying concept of transfecting a HIF-1α shRNA expression vector to block the HIF-1α holds promise as the clinical potential of gene therapy for cervical cancer.
Objective: Cervical cancer has become a major public health problem. The development of effective, systemic therapies for cervical cancer is highly desired. We show here that hypoxia inducible factor-1α (HIF-1α) was indicated as an attractive therapeutic molecular target for cervical cancer. Methods: Firstly, we observed the expressional level of HIF-1α in cervical cancer and Hela and Siha cell lines. Secondarily, by construct HIF-1α shRNA targeting human HIF-1α mRNA common sequence and transfecting it with plasmid to cervical cell, we detected the changes of HIF-1α and its downstream genes levels VEGF. Chen we injected selected stably transfected cell line into athymic nude mice to estimate its’ antitumor effects. Results: We observed that HIF-1α inhibition was related to down-regulated VEGF resulting in prevention of angiogenesis, then leading to slower-growing tumors. Confluence: The underlying concept of transfecting a HIF-1α shRNA expression vector to block the HIF-1α holds promise as t he clinical potential of gene therapy for cervical cancer.